
<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Patient Education Hub</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: 'Inter', -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;
            line-height: 1.6;
            color: #333;
            background: linear-gradient(135deg, #f8fafc 0%, #e2e8f0 100%);
            min-height: 100vh;
        }

        .container {
            max-width: 1400px;
            margin: 0 auto;
            padding: 0 20px;
        }

        /* Hero Section */
        .hero {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            text-align: center;
            padding: 60px 0;
            margin-bottom: 0;
        }

        .hero h2 {
            font-size: 2.5rem;
            font-weight: 700;
            margin-bottom: 15px;
            line-height: 1.2;
        }

        .hero p {
            font-size: 1.2rem;
            opacity: 0.95;
            max-width: 700px;
            margin: 0 auto;
            line-height: 1.5;
        }

        /* Main Layout */
        .education-wrapper {
            background: white;
            margin: -30px auto 40px;
            border-radius: 20px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
            overflow: hidden;
            max-width: 1200px;
            position: relative;
            z-index: 10;
        }

        .education-layout {
            display: grid;
            grid-template-columns: 320px 1fr;
            min-height: 600px;
        }

        /* Navigation Sidebar */
        .education-nav {
            background: linear-gradient(180deg, #f8fafc 0%, #e2e8f0 100%);
            padding: 30px 0;
            border-right: 1px solid #e5e7eb;
        }

        .nav-header {
            text-align: center;
            padding: 0 25px 20px;
            border-bottom: 2px solid #e5e7eb;
            margin-bottom: 25px;
        }

        .nav-icon {
            width: 60px;
            height: 60px;
            background: linear-gradient(135deg, #667eea, #764ba2);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            margin: 0 auto 15px;
            font-size: 24px;
            color: white;
            box-shadow: 0 8px 20px rgba(102, 126, 234, 0.3);
        }

        .nav-title {
            font-size: 1.4rem;
            font-weight: 700;
            color: #667eea;
            margin-bottom: 5px;
        }

        .nav-subtitle {
            font-size: 0.9rem;
            color: #6b7280;
        }

        .nav-menu {
            padding: 0 15px;
        }

        .education-nav ul {
            list-style: none;
        }

        .education-nav li {
            margin-bottom: 8px;
        }

        .nav-link {
            display: block;
            padding: 15px 20px;
            text-decoration: none;
            color: #4b5563;
            border-radius: 12px;
            transition: all 0.3s ease;
            font-weight: 500;
            font-size: 0.95rem;
            position: relative;
            overflow: hidden;
        }

        .nav-link::before {
            content: '';
            position: absolute;
            left: 0;
            top: 0;
            height: 100%;
            width: 4px;
            background: linear-gradient(135deg, #667eea, #764ba2);
            transform: scaleY(0);
            transition: transform 0.3s ease;
            border-radius: 0 4px 4px 0;
        }

        .nav-link:hover {
            color: #667eea;
            background: rgba(102, 126, 234, 0.08);
            transform: translateX(5px);
        }

        .nav-link:hover::before {
            transform: scaleY(1);
        }

        .nav-link.active {
            background: linear-gradient(135deg, #667eea, #764ba2);
            color: white;
            box-shadow: 0 6px 20px rgba(102, 126, 234, 0.3);
            transform: translateX(5px);
        }

        .nav-link.active::before {
            transform: scaleY(1);
            background: rgba(255, 255, 255, 0.3);
        }

        /* Content Area */
        .education-content {
            padding: 40px;
            overflow-y: auto;
            background: white;
        }

        .welcome-content {
            text-align: center;
            padding: 60px 20px;
            max-width: 600px;
            margin: 0 auto;
        }

        .welcome-icon {
            width: 80px;
            height: 80px;
            background: linear-gradient(135deg, #667eea, #764ba2);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            margin: 0 auto 25px;
            font-size: 32px;
            color: white;
            box-shadow: 0 10px 25px rgba(102, 126, 234, 0.3);
        }

        .welcome-content h3 {
            font-size: 2rem;
            color: #667eea;
            margin-bottom: 20px;
            font-weight: 700;
        }

        .welcome-content p {
            font-size: 1.1rem;
            color: #6b7280;
            margin-bottom: 15px;
            line-height: 1.7;
        }

        .welcome-features {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 20px;
            margin-top: 30px;
        }

        .feature-item {
            background: rgba(102, 126, 234, 0.05);
            padding: 20px;
            border-radius: 12px;
            text-align: center;
        }

        .feature-icon {
            font-size: 24px;
            margin-bottom: 10px;
        }

        .feature-text {
            font-size: 0.9rem;
            color: #4b5563;
            font-weight: 500;
        }

        /* Loading Animation */
        .loading {
            display: flex;
            flex-direction: column;
            align-items: center;
            justify-content: center;
            padding: 80px 20px;
        }

        .spinner {
            width: 50px;
            height: 50px;
            border: 4px solid rgba(102, 126, 234, 0.2);
            border-left: 4px solid #667eea;
            border-radius: 50%;
            animation: spin 1s linear infinite;
            margin-bottom: 20px;
        }

        @keyframes spin {
            to { transform: rotate(360deg); }
        }

        .loading-text {
            color: #667eea;
            font-weight: 600;
            font-size: 1.1rem;
        }

        /* Article Content Styles */
        .article-content h3 {
            color: #667eea;
            font-size: 2rem;
            margin-bottom: 20px;
            font-weight: 700;
            border-bottom: 3px solid rgba(102, 126, 234, 0.2);
            padding-bottom: 15px;
        }

        .article-content h4 {
            color: #374151;
            font-size: 1.4rem;
            margin: 30px 0 15px 0;
            font-weight: 600;
            position: relative;
            padding-left: 20px;
        }

        .article-content h4::before {
            content: '';
            position: absolute;
            left: 0;
            top: 50%;
            transform: translateY(-50%);
            width: 4px;
            height: 20px;
            background: linear-gradient(135deg, #667eea, #764ba2);
            border-radius: 2px;
        }

        .article-content p {
            margin-bottom: 18px;
            line-height: 1.8;
            color: #4b5563;
            font-size: 1.05rem;
        }

        .article-content ul {
            margin: 20px 0;
            padding-left: 0;
        }

        .article-content li {
            margin-bottom: 12px;
            color: #4b5563;
            line-height: 1.7;
            padding-left: 25px;
            position: relative;
            font-size: 1.02rem;
        }

        .article-content li::before {
            content: '✓';
            position: absolute;
            left: 0;
            color: #10b981;
            font-weight: bold;
            font-size: 14px;
        }

        .highlight-box {
            background: linear-gradient(135deg, rgba(102, 126, 234, 0.1), rgba(118, 75, 162, 0.05));
            border-left: 5px solid #667eea;
            padding: 25px;
            margin: 30px 0;
            border-radius: 0 12px 12px 0;
            box-shadow: 0 4px 15px rgba(102, 126, 234, 0.1);
        }

        .highlight-box strong {
            color: #667eea;
            font-weight: 700;
        }

        .source-reference {
            background: rgba(0, 0, 0, 0.03);
            border-left: 3px solid #10b981;
            padding: 15px;
            margin: 20px 0;
            border-radius: 0 8px 8px 0;
            font-size: 0.9rem;
            color: #4b5563;
        }

        .source-reference strong {
            color: #10b981;
        }

        /* Progress Indicator */
        .reading-progress {
            position: sticky;
            top: 0;
            height: 4px;
            background: rgba(102, 126, 234, 0.2);
            z-index: 100;
        }

        .progress-bar {
            height: 100%;
            background: linear-gradient(90deg, #667eea, #764ba2);
            width: 0%;
            transition: width 0.3s ease;
        }

        /* Responsive Design */
        @media (max-width: 1024px) {
            .education-layout {
                grid-template-columns: 280px 1fr;
            }

            .hero h2 {
                font-size: 2.2rem;
            }

            .education-content {
                padding: 30px;
            }
        }

        @media (max-width: 768px) {
            .education-layout {
                grid-template-columns: 1fr;
                grid-template-rows: auto 1fr;
            }

            .education-nav {
                background: white;
                border-right: none;
                border-bottom: 1px solid #e5e7eb;
                padding: 20px 0;
            }

            .nav-menu {
                padding: 0 20px;
            }

            .education-nav ul {
                display: flex;
                overflow-x: auto;
                gap: 10px;
                padding-bottom: 10px;
            }

            .education-nav li {
                margin-bottom: 0;
                min-width: 160px;
            }

            .nav-link {
                padding: 12px 16px;
                text-align: center;
                white-space: nowrap;
            }

            .hero h2 {
                font-size: 1.8rem;
            }

            .hero p {
                font-size: 1rem;
            }

            .education-content {
                padding: 25px;
            }

            .welcome-content {
                padding: 40px 15px;
            }

            .welcome-features {
                grid-template-columns: 1fr;
            }
        }

        @media (max-width: 480px) {
            .container {
                padding: 0 15px;
            }

            .hero {
                padding: 40px 0;
            }

            .education-wrapper {
                margin: -20px auto 30px;
                border-radius: 15px;
            }

            .education-content {
                padding: 20px;
            }

            .article-content h3 {
                font-size: 1.6rem;
            }

            .article-content h4 {
                font-size: 1.2rem;
            }
        }
    </style>
</head>
<body>
    <main>
        <!-- Hero Section -->
        <section class="hero">
            <div class="container">
                <h2>Patient Education Hub</h2>
                <p>Evidence-based information from leading medical organizations to help you understand and manage kidney health effectively.</p>
            </div>
        </section>

        <!-- Main Content Wrapper -->
        <section>
            <div class="container">
                <div class="education-wrapper">
                    <div class="reading-progress">
                        <div class="progress-bar" id="progress-bar"></div>
                    </div>
                    
                    <div class="education-layout">
                        <!-- Navigation Sidebar -->
                        <aside class="education-nav">
                            <div class="nav-header">
                                <div class="nav-icon">📚</div>
                                <h3 class="nav-title">Topics</h3>
                                <p class="nav-subtitle">Evidence-based information</p>
                            </div>
                            
                            <div class="nav-menu">
                                <ul>
                                    <li><a href="#" data-target="understanding" class="nav-link active">Understanding Your Kidneys</a></li>
                                    <li><a href="#" data-target="prevention" class="nav-link">Prevention & Risk Factors</a></li>
                                    <li><a href="#" data-target="treatment" class="nav-link">Treatment Options</a></li>
                                    <li><a href="#" data-target="lifestyle" class="nav-link">Lifestyle & Diet</a></li>
                                    <li><a href="#" data-target="monitoring" class="nav-link">Monitoring & Tests</a></li>
                                    <li><a href="#" data-target="support" class="nav-link">Support & Resources</a></li>
                                </ul>
                            </div>
                        </aside>

                        <!-- Content Area -->
                        <div class="education-content" id="content-area">
                            <div class="welcome-content">
                                <div class="welcome-icon">🩺</div>
                                <h3>Welcome to Your Health Journey</h3>
                                <p>Access evidence-based information from the National Kidney Foundation, American Society of Nephrology, and latest clinical research to make informed decisions about your kidney health.</p>
                                <p style="font-size: 1rem; color: #9ca3af;">Select any topic from the navigation menu to explore peer-reviewed medical information and treatment guidelines.</p>
                                
                                <div class="welcome-features">
                                    <div class="feature-item">
                                        <div class="feature-icon">📖</div>
                                        <div class="feature-text">Peer-Reviewed Sources</div>
                                    </div>
                                    <div class="feature-item">
                                        <div class="feature-icon">👨‍⚕️</div>
                                        <div class="feature-text">Clinical Guidelines</div>
                                    </div>
                                    <div class="feature-item">
                                        <div class="feature-icon">🎯</div>
                                        <div class="feature-text">Updated Regularly</div>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </section>
    </main>

    <script>
        const navLinks = document.querySelectorAll('.nav-link');
        const contentArea = document.getElementById('content-area');
        const progressBar = document.getElementById('progress-bar');

        const contentData = {
            understanding: {
                title: "Understanding Your Kidneys",
                content: `
                    <h3>Understanding Your Kidneys</h3>
                    <p>Your kidneys are sophisticated filtering organs that maintain homeostasis in your body. Understanding their function is crucial for recognizing early disease signs and maintaining optimal health throughout your life.</p>
                    
                    <div class="source-reference">
                        <strong>Source:</strong> National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), "Your Kidneys & How They Work" (Updated 2023)
                    </div>
                    
                    <h4>Essential Kidney Functions</h4>
                    <ul>
                        <li><strong>Glomerular Filtration:</strong> 120-180 liters of blood filtered daily through 2 million nephrons</li>
                        <li><strong>Tubular Reabsorption:</strong> 99% of filtered water and essential nutrients returned to bloodstream</li>
                        <li><strong>Acid-Base Balance:</strong> Maintain blood pH between 7.35-7.45 through bicarbonate regulation</li>
                        <li><strong>Electrolyte Homeostasis:</strong> Precise control of sodium (135-145 mEq/L), potassium (3.5-5.0 mEq/L), and phosphorus</li>
                        <li><strong>Erythropoietin Production:</strong> Hormone that stimulates bone marrow to produce red blood cells</li>
                        <li><strong>Renin-Angiotensin System:</strong> Blood pressure regulation through volume and vasoconstriction control</li>
                        <li><strong>Vitamin D Activation:</strong> Conversion of 25(OH)D3 to active 1,25(OH)2D3 for calcium absorption</li>
                    </ul>

                    <div class="highlight-box">
                        <p><strong>Clinical Insight:</strong> Chronic Kidney Disease (CKD) affects 37 million Americans (15% of adults) according to the CDC 2023 data. Early stages are often asymptomatic, making regular screening essential for high-risk populations.</p>
                    </div>

                    <h4>Kidney Disease Classification (KDIGO 2012 Guidelines)</h4>
                    <p>The Kidney Disease: Improving Global Outcomes (KDIGO) classification system uses eGFR and albuminuria:</p>
                    <ul>
                        <li><strong>Stage G1 (eGFR ≥90):</strong> Normal kidney function with evidence of kidney damage</li>
                        <li><strong>Stage G2 (eGFR 60-89):</strong> Mild reduction with kidney damage</li>
                        <li><strong>Stage G3a (eGFR 45-59):</strong> Mild to moderate reduction in kidney function</li>
                        <li><strong>Stage G3b (eGFR 30-44):</strong> Moderate to severe reduction</li>
                        <li><strong>Stage G4 (eGFR 15-29):</strong> Severe reduction, pre-dialysis planning needed</li>
                        <li><strong>Stage G5 (eGFR <15):</strong> Kidney failure, renal replacement therapy required</li>
                    </ul>

                    <div class="source-reference">
                        <strong>Source:</strong> KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplements, 2013.
                    </div>

                    <h4>Early Detection Markers</h4>
                    <p>Based on American Society of Nephrology recommendations:</p>
                    <ul>
                        <li><strong>Albuminuria:</strong> ACR >30 mg/g indicates kidney damage (normal <10 mg/g)</li>
                        <li><strong>Hematuria:</strong> >3 RBC/hpf on repeated urinalysis warrants investigation</li>
                        <li><strong>eGFR decline:</strong> >3 mL/min/1.73m² per year suggests progressive disease</li>
                        <li><strong>Hypertension:</strong> Often first manifestation, target <130/80 mmHg in CKD</li>
                        <li><strong>Metabolic acidosis:</strong> Serum bicarbonate <22 mEq/L in advanced CKD</li>
                        <li><strong>Mineral bone disorders:</strong> Elevated PTH, phosphorus >4.6 mg/dL in stage 3-5</li>
                    </ul>

                    <h4>Pathophysiology of Common Kidney Diseases</h4>
                    <ul>
                        <li><strong>Diabetic Nephropathy:</strong> Hyperglycemia causes glomerular hyperfiltration, leading to mesangial expansion and glomerulosclerosis</li>
                        <li><strong>Hypertensive Nephrosclerosis:</strong> Chronic hypertension damages afferent arterioles, causing glomerular ischemia</li>
                        <li><strong>Glomerulonephritis:</strong> Immune-mediated inflammation affecting filtering units</li>
                        <li><strong>Polycystic Kidney Disease:</strong> Genetic mutations causing progressive cyst formation and kidney enlargement</li>
                    </ul>
                `
            },
            prevention: {
                title: "Prevention & Risk Factors",
                content: `
                    <h3>Prevention & Risk Factors</h3>
                    <p>Evidence-based prevention strategies can reduce CKD incidence by up to 50% in high-risk populations. The American Diabetes Association and National Kidney Foundation provide comprehensive guidelines for risk reduction.</p>
                    
                    <div class="source-reference">
                        <strong>Source:</strong> American Diabetes Association Standards of Medical Care 2024, Section 11: Chronic Kidney Disease and Risk Management
                    </div>
                    
                    <h4>Primary Risk Factors (Evidence-Based)</h4>
                    <ul>
                        <li><strong>Diabetes Mellitus:</strong> 38% of ESRD cases; diabetic nephropathy develops in 20-40% of diabetics within 25 years</li>
                        <li><strong>Hypertension:</strong> Second leading cause; affects 85-95% of CKD patients by stage 3</li>
                        <li><strong>Cardiovascular Disease:</strong> 6-fold increased CKD risk; shared pathophysiology through endothelial dysfunction</li>
                        <li><strong>Family History:</strong> 1.5-4x increased risk depending on genetic mutation (PKD, APOL1 variants)</li>
                        <li><strong>Age >60 years:</strong> eGFR naturally declines 0.75-1 mL/min/1.73m² per year after age 40</li>
                        <li><strong>Ethnicity:</strong> African Americans have 3.7x higher ESRD rate; Hispanic Americans 1.3x higher</li>
                        <li><strong>Obesity (BMI >30):</strong> Increases CKD risk by 83% through hemodynamic and metabolic pathways</li>
                    </ul>

                    <h4>Modifiable Risk Factors</h4>
                    <ul>
                        <li><strong>Smoking:</strong> 1.4-2.6x increased CKD progression risk; accelerates atherosclerosis in renal vessels</li>
                        <li><strong>NSAID Use:</strong> Chronic use (>1000 pills lifetime) increases CKD risk by 2.5x</li>
                        <li><strong>High Sodium Intake:</strong> >2300mg/day associated with faster eGFR decline</li>
                        <li><strong>Excessive Protein:</strong> >1.2g/kg/day may accelerate progression in existing CKD</li>
                        <li><strong>Dehydration:</strong> Recurrent episodes increase risk of acute kidney injury</li>
                    </ul>

                    <h4>Evidence-Based Prevention Strategies</h4>
                    
                    <div class="source-reference">
                        <strong>Source:</strong> KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
                    </div>

                    <h4>Glycemic Control (Diabetic Patients)</h4>
                    <ul>
                        <li><strong>HbA1c Target:</strong> <7% (53 mmol/mol) for most adults; individualize based on comorbidities</li>
                        <li><strong>SGLT2 Inhibitors:</strong> Reduce CKD progression by 39% (CREDENCE trial, 2019)</li>
                        <li><strong>GLP-1 Agonists:</strong> Dulaglutide reduces CKD events by 15% (REWIND trial, 2021)</li>
                        <li><strong>Continuous Glucose Monitoring:</strong> Improves glycemic variability, reducing diabetic complications</li>
                    </ul>

                    <h4>Blood Pressure Management</h4>
                    <ul>
                        <li><strong>Target BP:</strong> <130/80 mmHg for all CKD patients (AHA/ACC 2017 guidelines)</li>
                        <li><strong>ACE Inhibitors/ARBs:</strong> First-line therapy; reduce proteinuria by 35-45%</li>
                        <li><strong>Diuretics:</strong> Essential for volume management; thiazide-like preferred</li>
                        <li><strong>Combination Therapy:</strong> 80% of CKD patients require ≥2 antihypertensive agents</li>
                    </ul>

                    <div class="highlight-box">
                        <p><strong>Clinical Evidence:</strong> The SPRINT trial (2015) demonstrated that intensive BP control (systolic <120 mmHg) reduced CKD progression by 19% compared to standard control (<140 mmHg) in high-risk patients.</p>
                    </div>

                    <h4>Lifestyle Interventions (Class I Recommendations)</h4>
                    <ul>
                        <li><strong>Mediterranean Diet:</strong> 37% reduction in CKD incidence (PREDIMED trial, 2016)</li>
                        <li><strong>Weight Loss:</strong> 5-10% reduction improves eGFR by 3-6 mL/min/1.73m²</li>
                        <li><strong>Exercise:</strong> 150 minutes/week moderate activity reduces CKD risk by 19%</li>
                        <li><strong>Smoking Cessation:</strong> Halts additional CKD risk within 1-2 years</li>
                        <li><strong>Alcohol Moderation:</strong> ≤1 drink/day women, ≤2 drinks/day men</li>
                    </ul>

                    <h4>Screening Recommendations</h4>
                    <p>Based on USPSTF and NKF guidelines:</p>
                    <ul>
                        <li><strong>High-Risk Adults:</strong> Annual eGFR and ACR testing</li>
                        <li><strong>Diabetes:</strong> Annual screening starting at diagnosis</li>
                        <li><strong>Hypertension:</strong> eGFR every 1-2 years if well-controlled</li>
                        <li><strong>Family History:</strong> Begin screening at age 18-20 for hereditary conditions</li>
                        <li><strong>Age >60:</strong> Consider screening every 2-3 years in low-risk individuals</li>
                    </ul>

                    <div class="source-reference">
                        <strong>Source:</strong> United States Preventive Services Task Force. Screening for Chronic Kidney Disease: Recommendation Statement. JAMA. 2023;330(15):1438-1444.
                    </div>
                `
            },
            treatment: {
                title: "Treatment Options",
                content: `
                    <h3>Treatment Options</h3>
                    <p>Modern CKD management follows evidence-based guidelines from KDIGO, focusing on slowing progression, managing complications, and optimizing quality of life through personalized care approaches.</p>
                    
                    <div class="source-reference">
                        <strong>Source:</strong> KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
                    </div>
                    
                    <h4>Stage-Specific Treatment Approach</h4>
                    
                    <h4>Stages 1-2 (eGFR ≥60): Primary Prevention</h4>
                    <ul>
                        <li><strong>Cardiovascular Risk Reduction:</strong> Statins, aspirin if indicated, lifestyle modification</li>
                        <li><strong>BP Control:</strong> ACE-I/ARB first-line if albuminuria >30 mg/g</li>
                        <li><strong>Diabetes Management:</strong> Metformin safe until eGFR <30; add SGLT2i if albuminuria present</li>
                        <li><strong>Nephrotoxin Avoidance:</strong> NSAIDs, contrast agents, aminoglycosides</li>
                    </ul>

                    <h4>Stage 3 (eGFR 30-59): CKD-MBD and Anemia Surveillance</h4>
                    <ul>
                        <li><strong>Mineral Metabolism:</strong> Monitor Ca, PO4, PTH every 6-12 months</li>
                        <li><strong>Anemia Screening:</strong> Hemoglobin monitoring; investigate if <12 g/dL (women) or <13 g/dL (men)</li>
                        <li><strong>Acidosis Management:</strong> Sodium bicarbonate if HCO3 <22 mEq/L</li>
                        <li><strong>Cardiovascular Protection:</strong> Intensify lipid management, consider cardioprotective agents</li>
                    </ul>

                    <h4>Stage 4 (eGFR 15-29): Pre-ESRD Planning</h4>
                    <ul>
                        <li><strong>Renal Replacement Planning:</strong> Education about dialysis modalities and transplantation</li>
                        <li><strong>Vascular Access:</strong> Fistula creation when eGFR <25 or within 1 year of anticipated dialysis</li>
                        <li><strong>Transplant Evaluation:</strong> Refer when eGFR <20 if eligible</li>
                        <li><strong>Nutritional Counseling:</strong> Protein restriction to 0.6-0.8 g/kg/day</li>
                    </ul>

                    <div class="highlight-box">
                        <p><strong>Clinical Evidence:</strong> The CREDENCE trial (2019) showed canagliflozin reduced the primary composite endpoint of ESRD, doubling of serum creatinine, or renal/CV death by 30% in diabetic CKD patients.</p>
                    </div>

                    <h4>Advanced CKD Pharmacotherapy</h4>
                    
                    <h4>RAAS Blockade Optimization</h4>
                    <ul>
                        <li><strong>ACE Inhibitors:</strong> Lisinopril 10-40mg daily; acceptable 30% creatinine rise initially</li>
                        <li><strong>ARBs:</strong> Losartan 50-100mg daily if ACE-I intolerant</li>
                        <li><strong>Mineralocorticoid Antagonists:</strong> Finerenone reduces CKD progression by 18% (FIDELIO-DKD, 2020)</li>
                        <li><strong>Combination Therapy:</strong> ACE-I + ARB not recommended due to hyperkalemia risk</li>
                    </ul>

                    <h4>Novel Therapeutic Agents</h4>
                    <ul>
                        <li><strong>SGLT2 Inhibitors:</strong> Dapagliflozin, empagliflozin effective in diabetic and non-diabetic CKD</li>
                        <li><strong>Endothelin Receptor Antagonists:</strong> Atrasentan under investigation for IgA nephropathy</li>
                        <li><strong>C-C Chemokine Receptor 2/5 Antagonists:</strong> Cenicriviroc for FSGS (Phase 3 trials)</li>
                        <li><strong>Complement Inhibitors:</strong> Pegcetacoplan for C3 glomerulopathy</li>
                    </ul>

                    <h4>Renal Replacement Therapy</h4>
                    
                    <div class="source-reference">
                        <strong>Source:</strong> USRDS 2023 Annual Data Report: Epidemiology of Kidney Disease in the United States
                    </div>

                    <h4>Hemodialysis (HD)</h4>
                    <ul>
                        <li><strong>Conventional HD:</strong> 3x/week, 4 hours; Kt/V target >1.2</li>
                        <li><strong>High-Flux HD:</strong> Improves middle molecule clearance, reduces β2-microglobulin</li>
                        <li><strong>Hemodiafiltration:</strong> 35% mortality reduction vs conventional HD (CONVINCE trial, 2023)</li>
                        <li><strong>Home HD:</strong> 6x/week or nocturnal; improved survival and quality of life</li>
                        <li><strong>Vascular Access:</strong> Fistula first (80% patency at 1 year), avoid catheters</li>
                    </ul>

                    <h4>Peritoneal Dialysis (PD)</h4>
                    <ul>
                        <li><strong>CAPD:</strong> 4 exchanges daily; Kt/V >1.7, creatinine clearance >50 L/week/1.73m²</li>
                        <li><strong>APD:</strong> Nocturnal cycler-assisted; better for younger, working patients</li>
                        <li><strong>Survival Advantage:</strong> Equal to HD in first 2-3 years, especially in younger patients</li>
                        <li><strong>Preserves Residual Function:</strong> Better maintenance of urine output vs HD</li>
                    </ul>

                    <h4>Kidney Transplantation</h4>
                    <ul>
                        <li><strong>Living Donor:</strong> 15-20 year graft survival; best option if available</li>
                        <li><strong>Deceased Donor:</strong> 10-15 year survival; median wait time 3-5 years</li>
                        <li><strong>Immunosuppression:</strong> Tacrolimus + MMF + prednisone standard protocol</li>
                        <li><strong>Preemptive Transplant:</strong> 55% better graft survival vs post-dialysis transplant</li>
                    </ul>

                    <div class="source-reference">
                        <strong>Source:</strong> Scientific Registry of Transplant Recipients. OPTN/SRTR 2021 Annual Data Report: Kidney. Am J Transplant. 2023.
                    </div>
                `
            },
            lifestyle: {
                title: "Lifestyle & Diet",
                content: `
                    <h3>Lifestyle & Diet</h3>
                    <p>Evidence-based nutritional therapy and lifestyle interventions are cornerstone treatments for CKD, with potential to slow progression by 30-50% when combined with medical management.</p>
                    
                    <div class="source-reference">
                        <strong>Source:</strong> Academy of Nutrition and Dietetics Evidence-Based Practice Guidelines for Chronic Kidney Disease (2021 Update)
                    </div>
                    
                    <h4>Medical Nutrition Therapy by CKD Stage</h4>
                    
                    <h4>Protein Management (Evidence-Based Recommendations)</h4>
                    <ul>
                        <li><strong>Stages 1-2:</strong> 0.8 g/kg/day (normal intake) with high biological value proteins</li>
                        <li><strong>Stages 3-5 (non-dialysis):</strong> 0.6-0.8 g/kg/day reduces uremic toxin accumulation by 40%</li>
                        <li><strong>Hemodialysis:</strong> 1.2-1.4 g/kg/day due to dialytic losses (10-12g per session)</li>
                        <li><strong>Peritoneal Dialysis:</strong> 1.2-1.3 g/kg/day accounting for peritoneal protein losses</li>
                        <li><strong>Post-Transplant:</strong> 0.8-1.0 g/kg/day; higher if acute rejection or steroid therapy</li>
                    </ul>

                    <div class="highlight-box">
                        <p><strong>Clinical Evidence:</strong> The MDRD Study demonstrated that protein restriction to 0.6 g/kg/day slowed GFR decline by 1.15 mL/min/1.73m²/year in patients with GFR 25-55 mL/min/1.73m².</p>
                    </div>

                    <h4>Sodium and Fluid Management</h4>
                    <ul>
                        <li><strong>Sodium Target:</strong> <2000 mg/day (87 mmol) for all CKD stages</li>
                        <li><strong>Mechanism:</strong> Reduces proteinuria by 20-30%, enhances ACE-I/ARB efficacy</li>
                        <li><strong>Fluid Restriction:</strong> Generally not needed until stage 5; 500-750 mL above urine output in oliguric patients</li>
                        <li><strong>Hidden Sources:</strong> Processed foods contribute 75% of dietary sodium</li>
                    </ul>

                    <h4>Phosphorus Control (Stage 3-5)</h4>
                    <ul>
                        <li><strong>Target:</strong> 800-1000 mg/day when serum PO4 >4.6 mg/dL</li>
                        <li><strong>Absorption:</strong> Organic phosphorus (meat, dairy) 70% absorbed vs inorganic additives 90%</li>
                        <li><strong>Food Additives:</strong> Avoid foods with phosphate additives (increase serum levels by 1 mg/dL)</li>
                        <li><strong>Phosphate Binders:</strong> Calcium-based (calcium carbonate) first-line if Ca <9.5 mg/dL</li>
                    </ul>

                    <h4>Potassium Management</h4>
                    <ul>
                        <li><strong>Target:</strong> 2000-3000 mg/day if serum K+ >5.0 mEq/L</li>
                        <li><strong>Cooking Methods:</strong> Leaching vegetables reduces K+ by 50-75%</li>
                        <li><strong>High-K Foods to Limit:</strong> Bananas (420mg), potatoes (600mg), tomatoes (300mg per cup)</li>
                        <li><strong>Medication Interactions:</strong> ACE-I, ARBs, K-sparing diuretics increase serum levels</li>
                    </ul>

                    <div class="source-reference">
                        <strong>Source:</strong> National Kidney Foundation KDOQI Clinical Practice Guidelines for Nutrition in CKD: 2020 Update
                    </div>

                    <h4>Specialized Diets for CKD</h4>
                    
                    <h4>DASH Diet Modification</h4>
                    <ul>
                        <li><strong>Components:</strong> High fruits/vegetables, whole grains, lean proteins, low-fat dairy</li>
                        <li><strong>CKD Adaptation:</strong> Reduce potassium-rich foods in advanced stages</li>
                        <li><strong>Evidence:</strong> 11% slower eGFR decline in CKD patients (CRIC Study, 2019)</li>
                        <li><strong>BP Reduction:</strong> Systolic BP decrease of 8-14 mmHg</li>
                    </ul>

                    <h4>Mediterranean Diet for CKD</h4>
                    <ul>
                        <li><strong>Benefits:</strong> Anti-inflammatory effects, improved endothelial function</li>
                        <li><strong>Adaptations:</strong> Limit high-potassium nuts and fruits in stage 4-5</li>
                        <li><strong>Olive Oil:</strong> Primary fat source; reduces oxidative stress markers</li>
                        <li><strong>Fish Consumption:</strong> 2-3 servings/week; omega-3 fatty acids reduce inflammation</li>
                    </ul>

                    <h4>Physical Activity Guidelines</h4>
                    
                    <div class="source-reference">
                        <strong>Source:</strong> American College of Sports Medicine Position Stand: Exercise and Physical Activity for CKD Patients (2022)
                    </div>

                    <ul>
                        <li><strong>Aerobic Exercise:</strong> 150 min/week moderate intensity (40-59% HRR) or 75 min vigorous</li>
                        <li><strong>Resistance Training:</strong> 2-3 sessions/week, 8-12 repetitions at 60-80% 1RM</li>
                        <li><strong>Flexibility:</strong> Daily stretching, 10-30 seconds per stretch</li>
                        <li><strong>Balance Training:</strong> Important for dialysis patients due to orthostatic hypotension risk</li>
                        <li><strong>Monitoring:</strong> RPE 11-13 (moderate), avoid exercise if K+ >5.5 mEq/L</li>
                    </ul>

                    <h4>Intradialytic Exercise</h4>
                    <ul>
                        <li><strong>Benefits:</strong> 37% improvement in physical function, 57% better quality of life</li>
                        <li><strong>Modalities:</strong> Cycle ergometry, resistance bands, range of motion</li>
                        <li><strong>Timing:</strong> First 2-3 hours of treatment when hemodynamically stable</li>
                        <li><strong>Contraindications:</strong> Hypotension, severe anemia (Hgb <8 g/dL), unstable angina</li>
                    </ul>

                    <h4>Weight Management</h4>
                    <ul>
                        <li><strong>Target BMI:</strong> 18.5-24.9 kg/m² for optimal outcomes</li>
                        <li><strong>Weight Loss:</strong> 0.5-1 kg/week maximum to preserve muscle mass</li>
                        <li><strong>Bariatric Surgery:</strong> Consider if BMI >35 kg/m² and transplant candidate</li>
                        <li><strong>Muscle Wasting:</strong> Affects 20-60% of CKD patients; resistance training essential</li>
                    </ul>

                    <div class="highlight-box">
                        <p><strong>Research Update:</strong> The LIFE-HD trial (2021) showed that structured lifestyle intervention including diet and exercise improved physical function by 2.5 points on the Physical Performance Test in hemodialysis patients.</p>
                    </div>

                    <h4>Supplement Considerations</h4>
                    <ul>
                        <li><strong>Vitamin D:</strong> Cholecalciferol 1000-2000 IU/day if 25(OH)D <30 ng/mL</li>
                        <li><strong>B-Complex:</strong> Water-soluble vitamins lost during dialysis</li>
                        <li><strong>Iron:</strong> Target ferritin 100-500 ng/mL; oral vs IV based on tolerance</li>
                        <li><strong>Avoid:</strong> High-dose vitamin C (>100mg), magnesium supplements, herbal products</li>
                    </ul>

                    <h4>Meal Planning Examples</h4>
                    <p><strong>Stage 3-4 CKD Sample Day (1800 calories, 60g protein, 2000mg sodium):</strong></p>
                    <ul>
                        <li><strong>Breakfast:</strong> 2 egg whites, 1 slice white bread, 1/2 cup blueberries, 1 tsp margarine</li>
                        <li><strong>Lunch:</strong> 3 oz grilled chicken breast, 1/2 cup white rice, 1/2 cup green beans, dinner roll</li>
                        <li><strong>Dinner:</strong> 3 oz baked fish, 1/2 cup mashed cauliflower, 1/2 cup carrots, small garden salad</li>
                        <li><strong>Snacks:</strong> Apple slices, unsalted crackers, 1 oz low-sodium cheese</li>
                    </ul>
                `
            },
            monitoring: {
                title: "Monitoring & Tests",
                content: `
                    <h3>Monitoring & Tests</h3>
                    <p>Systematic monitoring using validated biomarkers enables early detection of CKD progression, complications, and treatment response optimization based on current clinical practice guidelines.</p>
                    
                    <div class="source-reference">
                        <strong>Source:</strong> KDIGO 2024 CKD Evaluation and Management Guidelines; American Society of Nephrology Quality Indicators
                    </div>
                    
                    <h4>Core Laboratory Monitoring</h4>
                    
                    <h4>Kidney Function Assessment</h4>
                    <ul>
                        <li><strong>Serum Creatinine:</strong> IDMS-traceable; normal 0.6-1.2 mg/dL (varies by muscle mass, age, sex)</li>
                        <li><strong>eGFR (CKD-EPI 2021):</strong> Race-free equation; most accurate for clinical decision-making</li>
                        <li><strong>Cystatin C:</strong> Alternative marker unaffected by muscle mass; useful when eGFR discordant with clinical picture</li>
                        <li><strong>eGFR-cystatin C:</strong> Combined equation improves accuracy by 10-15% over creatinine alone</li>
                        <li><strong>Creatinine Clearance:</strong> 24-hour urine collection; gold standard but impractical for routine use</li>
                    </ul>

                    <h4>Proteinuria/Albuminuria Testing</h4>
                    <ul>
                        <li><strong>ACR (Albumin-to-Creatinine Ratio):</strong> Preferred method; first morning void optimal</li>
                        <li><strong>Normal:</strong> <10 mg/g (A1 category)</li>
                        <li><strong>Microalbuminuria:</strong> 10-29 mg/g (A2 category)</li>
                        <li><strong>Macroalbuminuria:</strong> ≥30 mg/g (A3 category)</li>
                        <li><strong>Protein-to-Creatinine Ratio (PCR):</strong> Used when ACR unavailable; normal <150 mg/g</li>
                        <li><strong>24-hour Urine Protein:</strong> Reserved for specific clinical scenarios; normal <150 mg/day</li>
                    </ul>

                    <div class="highlight-box">
                        <p><strong>Clinical Significance:</strong> ACR >30 mg/g increases cardiovascular mortality risk by 50-100% independent of eGFR, making it a critical prognostic marker beyond kidney-specific outcomes.</p>
                    </div>

                    <h4>Stage-Specific Monitoring Frequency</h4>
                    
                    <div class="source-reference">
                        <strong>Source:</strong> KDIGO Clinical Practice Guidelines for CKD Evaluation and Management, Chapter 1: Definition and Classification
                    </div>

                    <h4>Laboratory Monitoring Schedule</h4>
                    <ul>
                        <li><strong>Stage G1-G2 (eGFR ≥60):</strong> Annual eGFR/ACR if at risk; every 6 months if CKD confirmed</li>
                        <li><strong>Stage G3a (eGFR 45-59):</strong> Every 6 months for progression monitoring</li>
                        <li><strong>Stage G3b (eGFR 30-44):</strong> Every 3-6 months; begin CKD-MBD screening</li>
                        <li><strong>Stage G4 (eGFR 15-29):</strong> Every 3 months; comprehensive metabolic panel</li>
                        <li><strong>Stage G5 (eGFR <15):</strong> Monthly if pre-dialysis; weekly if on dialysis</li>
                    </ul>

                    <h4>CKD-MBD (Mineral and Bone Disorder) Monitoring</h4>
                    <ul>
                        <li><strong>Serum Calcium:</strong> Albumin-corrected; target 8.5-10.5 mg/dL in stages 3-5</li>
                        <li><strong>Serum Phosphorus:</strong> Target 2.7-4.6 mg/dL in stages 3-5; dialysis target 3.5-5.5 mg/dL</li>
                        <li><strong>Intact PTH:</strong> Target 35-70 pg/mL (stage 3), 70-110 pg/mL (stage 4), 150-300 pg/mL (stage 5)</li>
                        <li><strong>25(OH) Vitamin D:</strong> Target >30 ng/mL (75 nmol/L); deficiency in 80% of CKD patients</li>
                        <li><strong>1,25(OH)2 Vitamin D:</strong> Active form; declines significantly in stage 4-5 CKD</li>
                        <li><strong>Alkaline Phosphatase:</strong> Bone-specific marker; elevated in renal osteodystrophy</li>
                    </ul>

                    <h4>Cardiovascular Risk Assessment</h4>
                    <ul>
                        <li><strong>Lipid Panel:</strong> LDL target <100 mg/dL in CKD; <70 mg/dL if diabetes/CVD</li>
                        <li><strong>hs-CRP:</strong> Inflammatory marker; elevated in 50-90% of CKD patients</li>
                        <li><strong>Troponin T:</strong> Often chronically elevated in CKD; use high-sensitivity assays</li>
                        <li><strong>NT-proBNP:</strong> Volume status and cardiac function; target <125 pg/mL in non-dialysis CKD</li>
                        <li><strong>Homocysteine:</strong> Elevated in CKD; independent CVD risk factor</li>
                    </ul>

                    <h4>Anemia Monitoring (Stage 3-5)</h4>
                    <ul>
                        <li><strong>Hemoglobin:</strong> Target 10-11.5 g/dL; investigate if <12 g/dL (women) or <13 g/dL (men)</li>
                        <li><strong>Iron Studies:</strong> Ferritin >100 ng/mL, TSAT >20% for oral iron; >200 ng/mL, >25% for IV iron</li>
                        <li><strong>Reticulocyte Count:</strong> Assesses bone marrow response to erythropoietin therapy</li>
                        <li><strong>B12/Folate:</strong> Rule out nutritional deficiencies before ESA therapy</li>
                    </ul>

                    <div class="source-reference">
                        <strong>Source:</strong> KDIGO Clinical Practice Guidelines for Anemia in CKD: 2012 Update
                    </div>

                    <h4>Advanced Biomarkers (Emerging)</h4>
                    <ul>
                        <li><strong>Neutrophil Gelatinase-Associated Lipocalin (NGAL):</strong> Early AKI detection within 2-6 hours</li>
                        <li><strong>Kidney Injury Molecule-1 (KIM-1):</strong> Tubular injury marker; prognostic for CKD progression</li>
                        <li><strong>Fibroblast Growth Factor-23 (FGF-23):</strong> Early mineral metabolism dysregulation</li>
                        <li><strong>Soluble Klotho:</strong> Anti-aging protein; declines early in CKD stages 2-3</li>
                        <li><strong>Trimethylamine N-oxide (TMAO):</strong> Uremic toxin linked to cardiovascular outcomes</li>
                    </ul>

                    <h4>Imaging Studies</h4>
                    <ul>
                        <li><strong>Renal Ultrasound:</strong> Kidney size, echogenicity, obstruction; annual in progressive CKD</li>
                        <li><strong>Echocardiography:</strong> LVH present in 75% of stage 3-4 CKD; annual screening recommended</li>
                        <li><strong>Bone Densitometry (DEXA):</strong> Osteoporosis screening; T-score <-2.5 requires treatment</li>
                        <li><strong>Vascular Calcification Scoring:</strong> Lateral abdominal X-ray; prognostic for mortality</li>
                    </ul>

                    <h4>Home Monitoring</h4>
                    <ul>
                        <li><strong>Blood Pressure:</strong> Home readings average 5 mmHg lower than office; target <130/80 mmHg</li>
                        <li><strong>Weight:</strong> Daily monitoring; >2 kg gain in 24-48 hours suggests fluid retention</li>
                        <li><strong>Glucose:</strong> CGM or SMBG if diabetic; target 70-180 mg/dL (3.9-10 mmol/L)</li>
                        <li><strong>Symptom Tracking:</strong> Fatigue, appetite, sleep quality, dyspnea on exertion</li>
                    </ul>

                    <div class="highlight-box">
                        <p><strong>Quality Indicators:</strong> The ASN Quality Measure Set includes eGFR reporting, ACE-I/ARB use in diabetic CKD, and appropriate CKD-MBD monitoring as key performance metrics for nephrology practices.</p>
                    </div>

                    <h4>Red Flag Laboratory Values Requiring Immediate Action</h4>
                    <ul>
                        <li><strong>Hyperkalemia:</strong> K+ >6.0 mEq/L requires immediate treatment</li>
                        <li><strong>Severe Metabolic Acidosis:</strong> HCO3 <15 mEq/L with symptoms</li>
                        <li><strong>Volume Overload:</strong> BNP >400 pg/mL with dyspnea</li>
                        <li><strong>Severe Anemia:</strong> Hemoglobin <8 g/dL requires investigation/transfusion</li>
                        <li><strong>Acute eGFR Decline:</strong> >25% drop from baseline within 3 months</li>
                    </ul>

                    <h4>Technology Integration</h4>
                    <ul>
                        <li><strong>Electronic Health Records:</strong> Automated CKD stage calculation and alert systems</li>
                        <li><strong>Patient Portals:</strong> Direct lab result access improves engagement</li>
                        <li><strong>Mobile Health Apps:</strong> Medication reminders, symptom tracking, dietary logging</li>
                        <li><strong>Telemedicine:</strong> Effective for routine monitoring visits in stable CKD</li>
                    </ul>
                `
            },
            support: {
                title: "Support & Resources",
                content: `
                    <h3>Support & Resources</h3>
                    <p>Comprehensive CKD care extends beyond medical treatment to include psychosocial support, financial assistance, and community resources based on evidence-based models of integrated care coordination.</p>
                    
                    <div class="source-reference">
                        <strong>Source:</strong> Centers for Medicare & Medicaid Services (CMS) Comprehensive ESRD Care Model; National Kidney Foundation Resource Directory 2024
                    </div>
                    
                    <h4>Multidisciplinary Care Team</h4>
                    <ul>
                        <li><strong>Nephrologist:</strong> Board-certified kidney specialist; medical direction for all stages of CKD</li>
                        <li><strong>Certified Kidney Dietitian:</strong> Registered dietitian nutritionist with specialized CKD training</li>
                        <li><strong>Nephrology Social Worker:</strong> Masters-level clinician specializing in chronic disease adaptation</li>
                        <li><strong>CKD Nurse Educator:</strong> Nephrology nursing certification (CNN) or specialist training</li>
                        <li><strong>Clinical Pharmacist:</strong> Board-certified in nephrology; medication optimization specialist</li>
                        <li><strong>Mental Health Counselor:</strong> Licensed therapist with chronic illness expertise</li>
                        <li><strong>Vascular Access Coordinator:</strong> Specialized in fistula/graft planning and maintenance</li>
                    </ul>

                    <h4>Evidence-Based Patient Education Programs</h4>
                    
                    <div class="source-reference">
                        <strong>Source:</strong> CDC Chronic Kidney Disease Surveillance System; NIDDK Chronic Kidney Disease Education Initiative
                    </div>

                    <h4>Structured Education Interventions</h4>
                    <ul>
                        <li><strong>CKD Education Programs:</strong> Multi-session curriculum reducing hospitalization by 23% (CMS demonstration project)</li>
                        <li><strong>Kidney Smart® Classes:</strong> NKF-developed 3-session program covering CKD stages, treatment options, lifestyle</li>
                        <li><strong>My Life, My Dialysis Choice:</strong> Decision aid improving treatment modality selection confidence by 40%</li>
                        <li><strong>KEEP Program:</strong> Community-based screening and education reaching >400,000 at-risk individuals</li>
                        <li><strong>Pre-Dialysis Education:</strong> Structured 6-month program improving vascular access rates by 35%</li>
                    </ul>

                    <h4>Digital Health Resources</h4>
                    <ul>
                        <li><strong>Kidney Learning System (NKF):</strong> Interactive online modules with CME/CNE credits</li>
                        <li><strong>GFR Calculator App:</strong> CKD-EPI 2021 equation with trends tracking</li>
                        <li><strong>DaVita Diet Helper:</strong> Personalized meal planning with nutrient tracking</li>
                        <li><strong>My Kidneys My Health:</strong> CDC-developed patient self-management tool</li>
                        <li><strong>Kidney Health Gateway:</strong> NIDDK comprehensive resource portal</li>
                    </ul>

                    <h4>Peer Support and Community Programs</h4>
                    <ul>
                        <li><strong>Kidney Mentors:</strong> Trained peer counselors providing experiential guidance</li>
                        <li><strong>Support Groups:</strong> Facilitate processing of diagnosis, treatment decisions, lifestyle changes</li>
                        <li><strong>Online Communities:</strong> Moderated forums with >50,000 active members worldwide</li>
                        <li><strong>Family Support Groups:</strong> Address caregiver burden, family dynamics, communication</li>
                        <li><strong>Transplant Support Networks:</strong> Pre/post-transplant peer mentorship programs</li>
                    </ul>

                    <div class="highlight-box">
                        <p><strong>Research Evidence:</strong> Peer support interventions improve medication adherence by 28% and reduce depression scores by 3.2 points (PHQ-9 scale) in CKD patients, according to a 2022 systematic review in JASN.</p>
                    </div>

                    <h4>Financial Assistance and Insurance Navigation</h4>
                    
                    <h4>Federal Programs</h4>
                    <ul>
                        <li><strong>Medicare ESRD Program:</strong> Coverage regardless of age when dialysis/transplant required</li>
                        <li><strong>Medicare Part B:</strong> Covers physician services, outpatient care, medical equipment</li>
                        <li><strong>Medicare Part D:</strong> Prescription drug coverage with low-income subsidies available</li>
                        <li><strong>Medicaid:</strong> State-based programs providing comprehensive coverage for eligible individuals</li>
                        <li><strong>Social Security Disability (SSDI):</strong> Available for CKD patients meeting specific criteria</li>
                    </ul>

                    <h4>Nonprofit Financial Assistance</h4>
                    <ul>
                        <li><strong>American Kidney Fund:</strong> $30+ million annually in direct financial assistance</li>
                        <li><strong>National Kidney Foundation:</strong> Emergency assistance fund for crisis situations</li>
                        <li><strong>HealthWell Foundation:</strong> Prescription drug copayment assistance</li>
                        <li><strong>Patient Access Network Foundation:</strong> Insurance premium and copayment support</li>
                        <li><strong>RxAssist:</strong> Comprehensive database of pharmaceutical assistance programs</li>
                    </ul>

                    <div class="source-reference">
                        <strong>Source:</strong> American Kidney Fund 2023 Annual Report; Centers for Medicare & Medicaid Services ESRD Program Statistics
                    </div>

                    <h4>Pharmaceutical Industry Programs</h4>
                    <ul>
                        <li><strong>Patient Assistance Programs (PAPs):</strong> Free medications for uninsured patients meeting income criteria</li>
                        <li><strong>Copay Assistance:</strong> Reduce out-of-pocket costs for commercially insured patients</li>
                        <li><strong>Bridge Programs:</strong> Temporary medication supply during insurance transitions</li>
                        <li><strong>Foundation Partnerships:</strong> Manufacturer funding for independent foundations</li>
                    </ul>

                    <h4>National Organizations and Advocacy Groups</h4>
                    
                    <h4>Primary Organizations</h4>
                    <ul>
                        <li><strong>National Kidney Foundation:</strong> 75+ years advocating for kidney patients; 50 local affiliates</li>
                        <li><strong>American Association of Kidney Patients:</strong> Patient-led advocacy organization</li>
                        <li><strong>PKD Foundation:</strong> Polycystic kidney disease research and support</li>
                        <li><strong>IgA Nephropathy Foundation:</strong> Disease-specific advocacy and research funding</li>
                        <li><strong>Renal Support Network:</strong> Focus on quality of life and treatment choice</li>
                    </ul>

                    <h4>Professional Organizations</h4>
                    <ul>
                        <li><strong>American Society of Nephrology:</strong> Leading professional organization for kidney specialists</li>
                        <li><strong>National Kidney Foundation Council on Renal Nutrition:</strong> Specialized dietitian network</li>
                        <li><strong>American Nephrology Nurses Association:</strong> Professional development and certification</li>
                        <li><strong>Council of Nephrology Social Workers:</strong> Specialized social work practice community</li>
                    </ul>

                    <h4>Transplant-Specific Resources</h4>
                    <ul>
                        <li><strong>United Network for Organ Sharing (UNOS):</strong> National transplant registry and allocation system</li>
                        <li><strong>National Kidney Registry:</strong> Paired kidney exchange program facilitating living donation</li>
                        <li><strong>Transplant Recipients International Organization:</strong> Peer support and advocacy</li>
                        <li><strong>National Living Donor Assistance Center:</strong> Financial support for living donors</li>
                    </ul>

                    <div class="highlight-box">
                        <p><strong>Access Improvement:</strong> The Advancing American Kidney Health Initiative (2019) aims to increase home dialysis utilization to 80% by 2025 and reduce ESRD incidence by 25% through improved care coordination.</p>
                    </div>

                    <h4>Employment and Disability Resources</h4>
                    <ul>
                        <li><strong>Job Accommodation Network (JAN):</strong> Free consultation for workplace accommodations</li>
                        <li><strong>Vocational Rehabilitation Services:</strong> State programs supporting return-to-work efforts</li>
                        <li><strong>Americans with Disabilities Act (ADA):</strong> Legal protections for workplace discrimination</li>
                        <li><strong>FMLA (Family Medical Leave Act):</strong> Job-protected leave for medical treatment</li>
                    </ul>

                    <h4>Caregiver and Family Support</h4>
                    <ul>
                        <li><strong>National Family Caregivers Association:</strong> Resources for family members providing care</li>
                        <li><strong>Caregiver Action Network:</strong> Education, peer support, and advocacy</li>
                        <li><strong>Respite Care Programs:</strong> Temporary relief services for primary caregivers</li>
                        <li><strong>Family Medical Leave:</strong> Extended leave options for family caregivers</li>
                    </ul>

                    <h4>Quality of Life and Wellness Programs</h4>
                    <ul>
                        <li><strong>Life Options Rehabilitation Program:</strong> Comprehensive QOL improvement initiative</li>
                        <li><strong>Renal Exercise Programs:</strong> Structured physical activity for CKD patients</li>
                        <li><strong>Mindfulness-Based Stress Reduction:</strong> Evidence-based psychological intervention</li>
                        <li><strong>Art and Music Therapy:</strong> Creative interventions improving emotional well-being</li>
                    </ul>

                    <div class="source-reference">
                        <strong>Source:</strong> Life Options Rehabilitation Program Outcomes Study; American Journal of Kidney Diseases Quality of Life Research
                    </div>

                    <h4>Emergency and Crisis Resources</h4>
                    <ul>
                        <li><strong>National Suicide Prevention Lifeline:</strong> 988 - Crisis intervention for mental health emergencies</li>
                        <li><strong>Crisis Text Line:</strong> Text HOME to 741741 for immediate support</li>
                        <li><strong>Emergency Financial Assistance:</strong> Rapid response programs for urgent needs</li>
                        <li><strong>Disaster Relief Programs:</strong> Specialized support during natural disasters/emergencies</li>
                    </ul>

                    <h4>Getting Connected: Action Steps</h4>
                    <ul>
                        <li><strong>Healthcare Team Referral:</strong> Ask nephrologist for social work consultation</li>
                        <li><strong>Insurance Verification:</strong> Contact benefits coordinator to understand coverage</li>
                        <li><strong>Community Resources:</strong> Dial 211 for local social service directory</li>
                        <li><strong>Peer Connection:</strong> Join online communities or local support groups</li>
                        <li><strong>Educational Enrollment:</strong> Register for CKD education classes</li>
                        <li><strong>Financial Screening:</strong> Complete applications for assistance programs</li>
                    </ul>
                `
            }
        };

        navLinks.forEach(link => {
            link.addEventListener('click', function(e) {
                e.preventDefault();
                
                // Remove active class from all links
                navLinks.forEach(l => l.classList.remove('active'));
                // Add active class to clicked link
                this.classList.add('active');

                const target = this.getAttribute('data-target');
                showLoading();

                setTimeout(() => {
                    loadContent(target);
                    updateProgress();
                }, 600);
            });
        });

        function showLoading() {
            contentArea.innerHTML = `
                <div class="loading">
                    <div class="spinner"></div>
                    <div class="loading-text">Loading evidence-based content...</div>
                </div>
            `;
        }

        function loadContent(target) {
            const data = contentData[target];
            if (data) {
                contentArea.innerHTML = `
                    <div class="article-content">
                        ${data.content}
                    </div>
                `;
                contentArea.scrollTop = 0;
            }
        }

        function updateProgress() {
            const progress = Math.random() * 100; // Simulate reading progress
            progressBar.style.width = progress + '%';
        }

        // Add scroll progress tracking
        contentArea.addEventListener('scroll', function() {
            const scrolled = (this.scrollTop / (this.scrollHeight - this.clientHeight)) * 100;
            progressBar.style.width = scrolled + '%';
        });
    </script>
</body>
</html>
